Researchers from the University of Arizona Cancer Center have identified a new method of activating specific molecules to target cancer cells while leaving healthy cells unharmed.
In their recent study, published in the Journal of the American Chemical Society, Wei Wang, PhD, and his team developed a new strategy called click-release proteolysis targeting chimeras, or crPROTACs, that allows for the activation and release of PROTACs only in cancer cells.
“The studies open a new way to deliver anti-cancer drugs to cancer cells,” Wang said.
“We are exploring the technology for the treatment of more challenging senescent cancer cells and other diseases.”
PROTACs are molecules that scientists designed to break down specific proteins in the body.
They are now explored as a potential treatment for cancer; however, one of the challenges is that they can be harmful to healthy cells due to uncontrolled protein breakdown.
Wang’s research focuses on an existing metabolic pathway in the human system, the ubiquitin-proteasome pathway, that normally targets proteins for degradation and recycling.
Wang’s strategy uses the pathway to specifically target cells at tumour sites, minimising premature drug activation and unwanted side effects.
The researchers found that the crPROTAC strategy successfully degraded proteins of interest in cancer cells.
“Unlike many other drug delivery strategies, this approach will be very precise in targeting just the tumour,” Wang said.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.